LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK).
Read the rest here:
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022
Robust recruitment activities experienced in closing weeks of September44 patients now enrolled
Follow this link:
Spectral Medical Provides Update on Tigris Clinical Trial
POTOMAC, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum”) (OTC: ONOV), a cybersecurity, electronic warfare, and IT services company, announced today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company’s application to list its shares of common stock (the “Common Stock”), has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and a one-for-twenty reverse stock split of the Common Stock effective on or about October 7, 2022. The ticker symbol for the Common Stock will change to “CTM” upon listing. Trading of the Common Stock is expected to commence on or about October 7, 2022. The new CUSIP for the Common Stock following the reverse stock split will be 14838T204.
More:
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange
Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.
Here is the original post:
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners
ZURICH, Switzerland, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Araris Biotech AG (“Araris” or “the Company”), a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology, today announced the closing of a $24 million financing round, bringing the total funds raised to $40 million to date.
See the original post here:
Araris Biotech Closes $24 Million Financing Round
Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board
Follow this link:
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council
Company announcement no. 16 - 224 October 2022
See the original post here:
Transactions in connection with share buy-back program
Industry veteran brings nearly 20 years of broad leadership experience in biopharma Industry veteran brings nearly 20 years of broad leadership experience in biopharma
See more here:
BlueSphere Bio Appoints Keir Loiacono as Chief Executive Officer
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022.
See the original post here:
Monthly information related to total number of voting rights and shares composing the share capital _September 30, 2022
Company announcement – No. 43 / 2022
The rest is here:
Zealand Pharma announces directed issue and private placement of approximately 4.5m new shares